Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease

Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study

Han Cheol Lee, Sang Rok Lee, Kyoo Rok Han, Cheol Woong Yu, Chang Gyu Park, Young Keun Ahn, Han Young Jin, Dong Woon Kim, Deok Kyu Cho, Seung Hyuk Choi, Sang Hyun Kim, Ki Yuk Chang, Seunghwan Lee, Wookbum Pyun, Nam Ho Lee, Woongchol Kang, Bum Kee Hong, Byung Ryul Cho, In Ho Chae, Joon Han Shin & 5 others Kookjin Chun, Doo Il Kim, Jae Won Lee, Young Jae Kim, Donghoon Choi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD). DP-R202 is a new sarpogrelate hydrochloride product with an improved dosage regimen compared with the agent in current use. The aim of this study was to compare the efficacy and safety profile of DP-R202 and Anplag& Tab in patients with PAD. Methods This study was a 12-week, multicenter, randomized, double-blinded, active-controlled, parallel group comparative Phase III clinical trial. One hundred fifty-one volunteer patients with PAD were randomized to receive DP-R202 300 mg once daily or Anplag Table 100 mg TID for 12 weeks. The primary end point was a change in patient assessment of lower leg pain intensity with the use of a visual analog scale (VAS) after 12 weeks of treatment. Results after 4, 8, and 12 weeks of treatment were compared with baseline and between treatment groups, and all patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs. Findings Two hundred thirty-one patients from 25 medical centers were assessed, and 151 were enrolled and randomly assigned to 1 of 2 treatment groups. Seventy-five patients received DP-R202 300 mg once daily and 76 patients received Anplag Table 100 mg TID for 12 weeks. Analysis of the change in lower leg pain intensity as determined by VAS score between baseline and week 12 (mean [SD], 20.72 [20.06] mm vs 15.55 [21.44] mm) suggested that DP-R202 was not inferior to Anplag Tab, and no significant differences were found in the secondary end points. No significant between-group differences were observed in the prevalence of drug-related clinical- or laboratory-determined AEs. For tolerability, no specific issue was found during the treatment period. Implication The results of this study suggest that DP-R202 was not inferior to Anplag Tab for efficacy in patients with PAD and indicated a good safety profile.

Original languageEnglish
Pages (from-to)557-573
Number of pages17
JournalClinical Therapeutics
Volume38
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Arteries
Safety
Peripheral Arterial Disease
Visual Analog Scale
Leg
Therapeutics
Pain
Phase III Clinical Trials
Serotonin Antagonists
Clinical Studies
Vital Signs
Platelet Aggregation Inhibitors
Volunteers
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lee, Han Cheol ; Lee, Sang Rok ; Han, Kyoo Rok ; Yu, Cheol Woong ; Park, Chang Gyu ; Ahn, Young Keun ; Jin, Han Young ; Kim, Dong Woon ; Cho, Deok Kyu ; Choi, Seung Hyuk ; Kim, Sang Hyun ; Chang, Ki Yuk ; Lee, Seunghwan ; Pyun, Wookbum ; Lee, Nam Ho ; Kang, Woongchol ; Hong, Bum Kee ; Cho, Byung Ryul ; Chae, In Ho ; Shin, Joon Han ; Chun, Kookjin ; Kim, Doo Il ; Lee, Jae Won ; Kim, Young Jae ; Choi, Donghoon. / Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease : Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study. In: Clinical Therapeutics. 2016 ; Vol. 38, No. 3. pp. 557-573.
@article{bf494745f4de45e48f9b021cd1fe89a3,
title = "Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study",
abstract = "Purpose Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD). DP-R202 is a new sarpogrelate hydrochloride product with an improved dosage regimen compared with the agent in current use. The aim of this study was to compare the efficacy and safety profile of DP-R202 and Anplag& Tab in patients with PAD. Methods This study was a 12-week, multicenter, randomized, double-blinded, active-controlled, parallel group comparative Phase III clinical trial. One hundred fifty-one volunteer patients with PAD were randomized to receive DP-R202 300 mg once daily or Anplag Table 100 mg TID for 12 weeks. The primary end point was a change in patient assessment of lower leg pain intensity with the use of a visual analog scale (VAS) after 12 weeks of treatment. Results after 4, 8, and 12 weeks of treatment were compared with baseline and between treatment groups, and all patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs. Findings Two hundred thirty-one patients from 25 medical centers were assessed, and 151 were enrolled and randomly assigned to 1 of 2 treatment groups. Seventy-five patients received DP-R202 300 mg once daily and 76 patients received Anplag Table 100 mg TID for 12 weeks. Analysis of the change in lower leg pain intensity as determined by VAS score between baseline and week 12 (mean [SD], 20.72 [20.06] mm vs 15.55 [21.44] mm) suggested that DP-R202 was not inferior to Anplag Tab, and no significant differences were found in the secondary end points. No significant between-group differences were observed in the prevalence of drug-related clinical- or laboratory-determined AEs. For tolerability, no specific issue was found during the treatment period. Implication The results of this study suggest that DP-R202 was not inferior to Anplag Tab for efficacy in patients with PAD and indicated a good safety profile.",
author = "Lee, {Han Cheol} and Lee, {Sang Rok} and Han, {Kyoo Rok} and Yu, {Cheol Woong} and Park, {Chang Gyu} and Ahn, {Young Keun} and Jin, {Han Young} and Kim, {Dong Woon} and Cho, {Deok Kyu} and Choi, {Seung Hyuk} and Kim, {Sang Hyun} and Chang, {Ki Yuk} and Seunghwan Lee and Wookbum Pyun and Lee, {Nam Ho} and Woongchol Kang and Hong, {Bum Kee} and Cho, {Byung Ryul} and Chae, {In Ho} and Shin, {Joon Han} and Kookjin Chun and Kim, {Doo Il} and Lee, {Jae Won} and Kim, {Young Jae} and Donghoon Choi",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.clinthera.2016.01.009",
language = "English",
volume = "38",
pages = "557--573",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "3",

}

Lee, HC, Lee, SR, Han, KR, Yu, CW, Park, CG, Ahn, YK, Jin, HY, Kim, DW, Cho, DK, Choi, SH, Kim, SH, Chang, KY, Lee, S, Pyun, W, Lee, NH, Kang, W, Hong, BK, Cho, BR, Chae, IH, Shin, JH, Chun, K, Kim, DI, Lee, JW, Kim, YJ & Choi, D 2016, 'Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study', Clinical Therapeutics, vol. 38, no. 3, pp. 557-573. https://doi.org/10.1016/j.clinthera.2016.01.009

Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease : Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study. / Lee, Han Cheol; Lee, Sang Rok; Han, Kyoo Rok; Yu, Cheol Woong; Park, Chang Gyu; Ahn, Young Keun; Jin, Han Young; Kim, Dong Woon; Cho, Deok Kyu; Choi, Seung Hyuk; Kim, Sang Hyun; Chang, Ki Yuk; Lee, Seunghwan; Pyun, Wookbum; Lee, Nam Ho; Kang, Woongchol; Hong, Bum Kee; Cho, Byung Ryul; Chae, In Ho; Shin, Joon Han; Chun, Kookjin; Kim, Doo Il; Lee, Jae Won; Kim, Young Jae; Choi, Donghoon.

In: Clinical Therapeutics, Vol. 38, No. 3, 01.03.2016, p. 557-573.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease

T2 - Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study

AU - Lee, Han Cheol

AU - Lee, Sang Rok

AU - Han, Kyoo Rok

AU - Yu, Cheol Woong

AU - Park, Chang Gyu

AU - Ahn, Young Keun

AU - Jin, Han Young

AU - Kim, Dong Woon

AU - Cho, Deok Kyu

AU - Choi, Seung Hyuk

AU - Kim, Sang Hyun

AU - Chang, Ki Yuk

AU - Lee, Seunghwan

AU - Pyun, Wookbum

AU - Lee, Nam Ho

AU - Kang, Woongchol

AU - Hong, Bum Kee

AU - Cho, Byung Ryul

AU - Chae, In Ho

AU - Shin, Joon Han

AU - Chun, Kookjin

AU - Kim, Doo Il

AU - Lee, Jae Won

AU - Kim, Young Jae

AU - Choi, Donghoon

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD). DP-R202 is a new sarpogrelate hydrochloride product with an improved dosage regimen compared with the agent in current use. The aim of this study was to compare the efficacy and safety profile of DP-R202 and Anplag& Tab in patients with PAD. Methods This study was a 12-week, multicenter, randomized, double-blinded, active-controlled, parallel group comparative Phase III clinical trial. One hundred fifty-one volunteer patients with PAD were randomized to receive DP-R202 300 mg once daily or Anplag Table 100 mg TID for 12 weeks. The primary end point was a change in patient assessment of lower leg pain intensity with the use of a visual analog scale (VAS) after 12 weeks of treatment. Results after 4, 8, and 12 weeks of treatment were compared with baseline and between treatment groups, and all patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs. Findings Two hundred thirty-one patients from 25 medical centers were assessed, and 151 were enrolled and randomly assigned to 1 of 2 treatment groups. Seventy-five patients received DP-R202 300 mg once daily and 76 patients received Anplag Table 100 mg TID for 12 weeks. Analysis of the change in lower leg pain intensity as determined by VAS score between baseline and week 12 (mean [SD], 20.72 [20.06] mm vs 15.55 [21.44] mm) suggested that DP-R202 was not inferior to Anplag Tab, and no significant differences were found in the secondary end points. No significant between-group differences were observed in the prevalence of drug-related clinical- or laboratory-determined AEs. For tolerability, no specific issue was found during the treatment period. Implication The results of this study suggest that DP-R202 was not inferior to Anplag Tab for efficacy in patients with PAD and indicated a good safety profile.

AB - Purpose Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD). DP-R202 is a new sarpogrelate hydrochloride product with an improved dosage regimen compared with the agent in current use. The aim of this study was to compare the efficacy and safety profile of DP-R202 and Anplag& Tab in patients with PAD. Methods This study was a 12-week, multicenter, randomized, double-blinded, active-controlled, parallel group comparative Phase III clinical trial. One hundred fifty-one volunteer patients with PAD were randomized to receive DP-R202 300 mg once daily or Anplag Table 100 mg TID for 12 weeks. The primary end point was a change in patient assessment of lower leg pain intensity with the use of a visual analog scale (VAS) after 12 weeks of treatment. Results after 4, 8, and 12 weeks of treatment were compared with baseline and between treatment groups, and all patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs. Findings Two hundred thirty-one patients from 25 medical centers were assessed, and 151 were enrolled and randomly assigned to 1 of 2 treatment groups. Seventy-five patients received DP-R202 300 mg once daily and 76 patients received Anplag Table 100 mg TID for 12 weeks. Analysis of the change in lower leg pain intensity as determined by VAS score between baseline and week 12 (mean [SD], 20.72 [20.06] mm vs 15.55 [21.44] mm) suggested that DP-R202 was not inferior to Anplag Tab, and no significant differences were found in the secondary end points. No significant between-group differences were observed in the prevalence of drug-related clinical- or laboratory-determined AEs. For tolerability, no specific issue was found during the treatment period. Implication The results of this study suggest that DP-R202 was not inferior to Anplag Tab for efficacy in patients with PAD and indicated a good safety profile.

UR - http://www.scopus.com/inward/record.url?scp=84960805964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960805964&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2016.01.009

DO - 10.1016/j.clinthera.2016.01.009

M3 - Article

VL - 38

SP - 557

EP - 573

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 3

ER -